EQUITY RESEARCH MEMO

Aurora Microplates

Generated 5/9/2026

Executive Summary

Conviction (model self-assessment)55/100

Aurora Microplates is a US-based manufacturer of premium microplates made from patented cyclo-olefin polymer (COP) material, designed to enhance reliability and precision in laboratory experiments. Founded in 2018 and headquartered in San Diego, the company serves the life science research and diagnostics sectors, with products trusted for high-throughput screening (HTS) and high-content screening (HCS). Its microplates offer superior optical clarity and performance compared to traditional polystyrene plates, addressing critical needs for accurate data in drug discovery and diagnostic applications. As a private company, Aurora is well-positioned to capitalize on the growing demand for advanced lab consumables driven by expanding R&D in biopharma and academic research. The company’s focus on proprietary materials and quality positions it as a specialized supplier in a competitive market, with potential for growth through product line extensions and strategic partnerships.

Upcoming Catalysts (preview)

  • Q3 2026Launch of Next-Generation COP Microplate with Enhanced Surface Chemistry70% success
  • Q4 2026Strategic Partnership with Major Diagnostics or Biopharma Company45% success
  • H1 2027FDA 510(k) Clearance for Microplate Used in In Vitro Diagnostic (IVD) Applications30% success
Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)